Grifols (NASDAQ: GRFS)
Grifols Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Grifols Company Info
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
News & Analysis
Why Shares of Grifols Were Up Tuesday
The company gave first-quarter numbers.
2 Healthcare Stocks That Could Help Make You a Fortune
Their dividends will be trickling into your account quarter after quarter.
Convalescent Plasma Found to Reduce COVID-19 Death Rate in New Study
The results provide more justification for the FDA to grant the substance emergency use authorization.
Better Coronavirus Stock: Grifols or Novartis?
Each company has a triad of COVID-19 projects, but they aren't in direct competition.
Who Can Donate Plasma for COVID-19 Patients?
Antibodies of recovered patients can help treat people who are infected with the novel coronavirus.
Is Rigel Pharmaceuticals Stock a Buy?
The real question is whether growing product sales can outpace increasing R&D expenses.
Is This Overlooked Stock Primed for More Growth?
Grifols isn't well-known, but it holds over 20% share in a $10 billion-plus market growing more than 6% a year.
3 Stocks Set to Beat the S&P Today
These three technology firms lead the way.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.